These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33101985)

  • 1. Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase.
    Hogan MJ; Stephens K; Smith E; Jalazo ER; Hendriksz CJ; Edwards LJ; Bjoraker KJ
    Mol Genet Metab Rep; 2020 Dec; 25():100669. PubMed ID: 33101985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
    Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
    Mol Genet Metab; 2022; 137(1-2):92-103. PubMed ID: 35961250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
    Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
    Mol Genet Metab; 2022; 137(1-2):127-139. PubMed ID: 36027721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II.
    Muenzer J; Vijayaraghavan S; Stein M; Kearney S; Wu Y; Alexanderian D
    Genet Med; 2022 Jul; 24(7):1437-1448. PubMed ID: 35588317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
    Burton BK; Jego V; Mikl J; Jones SA
    J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
    Burton BK; Whiteman DA;
    Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II.
    Seo JH; Kosuga M; Hamazaki T; Shintaku H; Okuyama T
    Mol Ther Methods Clin Dev; 2021 Jun; 21():67-75. PubMed ID: 33768130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).
    Muenzer J; Giugliani R; Scarpa M; Tylki-Szymańska A; Jego V; Beck M
    Orphanet J Rare Dis; 2017 Oct; 12(1):161. PubMed ID: 28974237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
    Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
    Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients.
    Giugliani R; Harmatz P; Jones SA; Mendelsohn NJ; Vellodi A; Qiu Y; Hendriksz CJ; Vijayaraghavan S; Whiteman DA; Pano A
    Mol Genet Metab Rep; 2017 Sep; 12():2-7. PubMed ID: 28243577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II.
    Ngu LH; Ong Peitee W; Leong HY; Chew HB
    Mol Genet Metab Rep; 2017 Sep; 12():28-32. PubMed ID: 28540187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
    Kim S; Whitley CB; Jarnes Utz JR
    Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys.
    Felice BR; Wright TL; Boyd RB; Butt MT; Pfeifer RW; Pan J; Ruiz JA; Heartlein MW; Calias P
    Toxicol Pathol; 2011 Aug; 39(5):879-92. PubMed ID: 21628718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
    Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.